The drug has been granted Breakthrough Therapy designation by the FDA for the treatment of chronic hepatitis delta (CHD).

Breakthrough Therapy Designation is designed to expedite the development and review of therapies that may show significant ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).

1,2 The diagnostic hallmark of hepatitis B virus carriers is detectable HBsAg in serum. When patients with chronic hepatitis B virus infection are superinfected with hepatitis D virus (also known as ...

US FDA grants breakthrough therapy designation to Bluejay Therapeutics’ brelovitug for treatment of chronic hepatitis delta: Redwood City, California Thursday, January 23, 2025, ...

It is also the eighth installment in a series on hepatitis D virus, a virusoid-like pathogen that causes serious human disease. You may read the others on Forbes or www.williamhaseltine.com.

The FDA has granted breakthrough therapy designation to Bluejay Therapeutics’ brelovitug for the treatment of chronic ... hepatitis B coinfection are at an increased risk for hepatitis D ...